Does EVOLOCUMAB Cause Product administered at inappropriate site? 338 Reports in FDA Database
Lower Your Cholesterol — The Natural Way
The Oxidized Cholesterol Strategy: a science-backed plan for heart health.
According to the FDA Adverse Event Reporting System (FAERS), 338 reports of Product administered at inappropriate site have been filed in association with EVOLOCUMAB (REPATHA). This represents 0.2% of all adverse event reports for EVOLOCUMAB.
338
Reports of Product administered at inappropriate site with EVOLOCUMAB
0.2%
of all EVOLOCUMAB reports
2
Deaths
4
Hospitalizations
How Dangerous Is Product administered at inappropriate site From EVOLOCUMAB?
Of the 338 reports, 2 (0.6%) resulted in death, 4 (1.2%) required hospitalization.
Is Product administered at inappropriate site Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for EVOLOCUMAB. However, 338 reports have been filed with the FAERS database.
What Other Side Effects Does EVOLOCUMAB Cause?
Device difficult to use (31,807)
Drug dose omission by device (23,957)
Wrong technique in product usage process (21,664)
Accidental exposure to product (16,160)
Injection site pain (9,988)
Product storage error (6,606)
Back pain (5,254)
Myalgia (5,061)
Drug dose omission (4,914)
Injection site bruising (4,409)
What Other Drugs Cause Product administered at inappropriate site?
DICLOFENAC (6,919)
MINOXIDIL (1,222)
TIRZEPATIDE (978)
DULAGLUTIDE (481)
DUPILUMAB (442)
NALTREXONE (436)
ADALIMUMAB (313)
HYDROXYPROGESTERONE CAPROATE (288)
ALIROCUMAB (262)
ABALOPARATIDE (232)
Which EVOLOCUMAB Alternatives Have Lower Product administered at inappropriate site Risk?
EVOLOCUMAB vs EXELON
EVOLOCUMAB vs EXEMESTANE
EVOLOCUMAB vs EXENATIDE
EVOLOCUMAB vs EXFORGE
EVOLOCUMAB vs EXJADE